Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Core Insights - Recursion and Enamine have collaborated to create 10 enriched screening libraries from over 15,000 newly synthesized compounds aimed at accelerating drug discovery against 100 key drug targets in challenging biological areas [1][3] - Enamine's REAL Space contains 64.9 billion make-on-demand molecules, providing a vast chemical library that enhances the drug discovery process when combined with Recursion's AI/ML platform [2][8] - The partnership allows for the development of smaller, focused libraries that outperform traditional high-throughput screening methods, thereby improving the efficiency of drug discovery [2][4] Company Overview - Recursion is a clinical stage TechBio company that utilizes its Recursion OS platform to generate one of the world's largest proprietary biological and chemical datasets, enabling advanced drug discovery [5][6] - Enamine is a Contract Research Organisation with a unique focus on integrated discovery services, offering access to 4.5 million screening compounds and 350,000 building blocks to accelerate drug discovery efforts [7] Technological Advancements - The collaboration leverages Recursion's sophisticated machine-learning algorithms to predict small molecule compatibility with protein targets, enhancing the selection process for promising drug candidates [2][3] - Enamine's REAL Space has been utilized in ultra-large virtual screening campaigns, and this partnership aims to explore its potential across multiple targets at scale [4][9]